21-23 August 2017

Boston, MA, USA


Day One
Tuesday 22 August, 2017

Day Two
Wednesday 23 August 2017


Disruptive Innovation: Translational Lessons from Current Market Approved Therapeutics

Overview & Review of Idiopathic Pulmonary Fibrosis Drug Development


• Highlighting the importance of new insights into the pathobiology of the disease and translating these into effective therapies
• Describing areas of exceptional need and potential opportunities to advance the IPF therapeutic research
• Discussing the performance and impact of in-phase clinical trials and the next steps needed in preclinical research to maximize clinical development

Biomarkers and Mechanistic Insights from Clinical Studies of Pirfenidone

  • Joe Arron Senior Director, Immunology Research, Genentech


• Elucidating discovered and implemented biomarkers related to specific signalling pathways and pathologic manifestations of disease in samples from patients enrolled in pirfenidone clinical studies
• Highlighting the role genetic and genomic studies of large IPF patient cohorts have played in revealing new biomarkers and insights into disease pathogenesis
• Exploring the possibilities of future clinical trials for novel therapeutic candidates done in combination with pirfenidone and/or nintedanib

The Translational Benefits of the Nintedanib MOA

  • Craig S. Conoscenti Medical Expert, Interstitial Lung Disease Clinical Development and Medical Affairs, Respiratory , Boehringer Ingelheim Pharmaceuticals, Inc.


• Understanding the Nintedanib MOA
• Application of Nintedanib’s MOA to different clinical targets
• Translational aspects of Nintedanib’s MOA

Session Q&A Panel

  • Joe Arron Senior Director, Immunology Research, Genentech
  • Gregory Cosgrove CMO, Pulmonary Fibrosis Foundation
  • Craig S. Conoscenti Medical Expert, Interstitial Lung Disease Clinical Development and Medical Affairs, Respiratory , Boehringer Ingelheim Pharmaceuticals, Inc.


• Defining a path towards disease modifying therapeutics
• Exploring the role of Pirfenidone and Nintedanib in the next generation of IPF therapeutics
• A look into the challenges that need to be overcome for effective combinations utilizing these molecules

Speed Networking & Morning Refreshments


This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IPF field and establish meaningful business relationships.

Emerging Platforms: The Development and Validation of Diagnostic and Prognostic Biomarkers

Collagen Biomarkers in IPF: Novel Insights into Disease Pathogenesis and Progression

  • Glenn Rosen Head, Discovery Fibrosis Biology, Bristol-Myers Squibb


• Identifying collagen turnover biomarkers that regulate collagen formation/degradation and their relevance in IPF
• Exploring the application of ex-vivo cell and tissue culture model systems and animal models for translational profiling of collagen turnover
• Evaluating collagen turnover biomarkers in IPF patients and their role as markers of disease activity, progression and drug response
• Highlighting the relevance of collagen biomarker profiles to other fibrotic diseases

Mining the Microbiome to Discover & Characterize Novel Pathways of Disease Onset and Progression


• Exploring localized changes in the bacterial microbiome, epithelial gene expression, antimicrobial peptides and host stress-response pathways on fibrosis onset
• Divulging the interrelationship between changes in the bacterial microbiome and clinical phenotype, gleaned by utilizing high throughput technologies and systems science approaches

Enhancing Anti-Inflammatory Effects as Measured by Serum IL-6; Lessons learned from the development of a novel, rationally-designed cell-penetrating peptide inhibitor of MK2


  • Highlighting the role of MK2, a terminal kinase in the TGF-β/p38 kinase cascade, in inflammation and fibrosis
  • Demonstrating the impact of combining a rationally designed peptide (MMI-0100), that mimics native substrates, with cell penetrant technology on target engagement
  • Showcasing the ability to effectively monitor the anti-inflammatory pharmacodynamics effects through measurement of serum IL-6

Session Q&A Panel

  • Glenn Rosen Head, Discovery Fibrosis Biology, Bristol-Myers Squibb
  • Fernando Martinez Executive Vice Chair of Medicine, Weill Cornell Medical College
  • Cynthia Lander Chief Executive Officer, Moerae Matrix, Inc.


• Discerning the current lack of measures that can be used in preclinical and early phase clinical trials
• Establishing a framework for evaluating the utility of incorporating IPF biomarkers across translational and clinical practice
• Highlighting the role of transcriptomic and proteomic studies in aiding biomarker discovery
• Discussing the necessity of careful longitudinal phenotyping of individuals with IPF in providing important insights into disease pathogenesis

Lunch & Networking

Recapitulating Disease in Physiologically Relevant Preclinical In Vitro Models

Utilizing Patient Derived Systems to Advance Drug Discovery in IPF


• Addressing the pitfalls of classical animal models being non representative and unpredictive of human IPF
• Genetic susceptibility and IPF: Highlighting the role of the epithelium in disease susceptibility for IPF
• Exploring advances in alternative systems and their impact on understanding epithelial cell biology and advancing drug discovery efforts

Establishment of an In Vitro Fibroblastic Focus Model Using IPF Patient Cells for Use in Drug Development


• Showcasing the use of human in vitro models in translational research
• Highlighting the development and characterization of the in vitro fibroblastic focus model
• Demonstrating the utility of this model in evaluating LOXL2-selective inhibitors by investigating their effects on collagen cross-link formation and matrix stiffness

Lung-On-A-Chip: A New Frontier for In Vitro Modelling of Lung Fibrosis Within Pharmaceutical Research

  • Joan Nichols Professor - Internal Medicine, Microbiology & Immunology, UTMB


• Supporting both lung function and initiation of an innate immune response through the bioengineering of human lung cells with a variety of cells involved in the innate immune response on a natural human lung acellular scaffold
• Demonstrating specific cellular responses including loss AEC II cells, proliferation of fibroblasts, production of fibrotic foci in the model were concomitant with induction of collagen production and development of fibrosis upon Bleomycin induction
• Highlighting the potential utility of this system in validating new therapeutic targets able to modify the progression of disease and toxicity testing
• Exploring genetic variation of human populations for specific human leucocyte antigen (HLA) subpopulations through the model

Session Q&A Panel


• Discussing the validity of these novel systems in accurately predicting in vivo outcomes
• Addressing the utility of advanced in vitro systems within the current paradigm of drug discovery
• Discerning a means to overcome the regulatory hurdles and approval standards for the preclinical applications of these novel systems
• Questioning the need to translate findings back to animal systems before making the leap to humans in the preclinical setting

Afternoon Refreshments & Networking

Exploring Heterogeneity Within the Mechanisms of Disease

High Content Imaging Screens to Identify Drugs that Impact Fibrosis


• The power of high content imaging screens to identify drugs effective against fibrosis
• The advantage of drug repurposing over conventional new chemical entities
• Examples of discovered drugs and mechanisms of action

Looking Beyond TGF-Beta to ROCK Inhibition as a Key Therapeutic Target in Fibrosis


• Overview of mechano-signal transduction in pulmonary fibrosis
• Role of ROCK in TGF-beta signaling and pro-fibrotic gene regulation
• Targeting ROCK in multiple fibrosis-associated pathogenic cell types

Mechanistic Relationships Between Fibrosis and Cancer: Translational Lessons from Preclinical and Clinical Studies of Fibrosis and Cancer

  • Seth Porter Vice President, Fibrosis Therapeutics, Fibrogen


• Demonstrating Pamrevlumab (anti-CTGF mAb, FG-3019) activity data in mouse models of cancer and fibrosis
• Highlighting parallel responses to Pamrevlumab in mouse models of pancreatic cancer and pulmonary fibrosis and clinical trials for pancreatic cancer and IPF, respectively
• Exploring preclinical models of cancer and fibrosis that reveal common mechanisms by which pamrevlumab acts

Session Q&A Panel


• Looking beyond dysregulated epithelial-mesenchymal interactions and highlighting emerging concepts in IPF pathogenesis including the role stress response pathways, cellular plasticity and mechanotransduction
• Exploring the role and current need for personalized medicine approaches to diagnose and treat IPF
• Discussing therapeutic approaches that target molecular pathways modulating aberrant cellular phenotypes and promote tissue homeostasis
• Exploring translational lessons from other therapeutic areas such as PAH and pancreatic cancer

Close of Conference Day One

Scientific Poster Session


After the formal presentations have finished, the learning and networking carries on. The Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere and continue to forge new and existing relationships.

During this session scientific posters will be presented on robust biomarker & diagnostic strategies, representative disease models aiding clinical translation and novel targets and novel mechanisms that offer a new means to tackle IPF.